Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$156.3MCash, Jun 2026
11moCash Runway (est.)
+21%Share Count, 1 Year
Follow LRMR by emailGet an email when LRMR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LRMR, unsubscribe in one click. Privacy
📣 What LRMR Says Is Next
second half of 2026 · “Following receipt of minutes from a successful Type B multidisciplinary pre-BLA meeting with the Food and Drug Administration (FDA), the first module of our rolling Biologics License Application (BLA) has been submitted, with completion expected in the second half of 2026.”
Company press release, Aug 4, 2026 · SEC filing
third quarter of 2027 · “$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway into the third quarter of 2027 Bala Cynwyd, PA, August 4, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.”
Company press release, Aug 4, 2026 · SEC filing
2H 2026 · “Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
LRMR reported $156.3M in cash and short-term investments (as of Jun 30, 2026) and used about $44.7M/quarter in operations, an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LRMR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.